Thursday, 22 June 2017

Curcumin kháng A431

Anti-apoptotic effects of curcumin on photosensitized human ...

Curcumin kháng A431

From Wikipedia, the free encyclopedia
Curcumin
Skeletal formula
Enol form
Skeletal formula
Keto form
Ball-and-stick model
Ball-and-stick model
Names
Pronunciation/ˈkɜːrkjᵿmɪn/
Preferred IUPAC name
(1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione
Other names
(1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione
Diferuloylmethane
Curcumin I
C.I. 75300
Natural Yellow 3
Identifiers
3D model (JSmol)
ChEBI
ChemSpider
E numberE100 (colours)
PubChem CID
UNII
Properties
C21H20O6
Molar mass368.39 g·mol−1
AppearanceBright yellow-orange powder
Melting point183 °C (361 °F; 456 K)
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
 verify (what is Yes ?)
Infobox references
Curcumin is a bright yellow chemical produced by some plants. It is the principal curcuminoid of turmeric (Curcuma longa), a member of the ginger family (Zingiberaceae). It is sold as an herbal supplementcosmetics ingredient, food flavoring, and food coloring.[1] As a food additive, its E number is E100.[2]
It was first isolated in 1815 when Vogel and Pierre Joseph Pelletier reported the isolation of a "yellow coloring-matter" from the rhizomes of turmeric and named it curcumin.[3] Although curcumin has been used historically in Ayurvedic medicine,[4] its potential for medicinal properties remains unproven and is questionable as a therapy when used orally.[5][6][7]
Chemically, curcumin is a diarylheptanoid, belonging to the group of curcuminoids, which are natural phenols responsible for turmeric's yellow color. It is a tautomeric compound existing in enolic form in organic solvents and as a keto form in water.[8]

Applications[edit]

The most common applications are as a dietary supplement, in cosmetics, as a food coloring, and as flavoring for foods such as turmeric-flavored beverages (Japan).[1]
Curcumin
Annual sales of curcumin have increased since 2012, largely due to an increase in its popularity as a dietary supplement.[1] It is increasingly popular in skincare products that are marketed as containing natural ingredients or dyes, especially in Asia.[1] The largest market is in North America, where sales exceeded US$20 million in 2014.[1]

Chemistry[edit]

Curcumin incorporates several functional groups whose structure was first identified in 1910.[9] The aromatic ring systems, which are phenols, are connected by two α,β-unsaturated carbonyl groups. The diketones form stable enols and are readily deprotonated to form enolates; the α,β-unsaturated carbonyl group is a good Michael acceptor and undergoes nucleophilic addition.
Curcumin is used as a complexometric indicator for boron.[10] It reacts with boric acid to form a red-colored compound, rosocyanine.

Biosynthesis[edit]

The biosynthetic route of curcumin is uncertain. In 1973, Roughly and Whiting proposed two mechanisms for curcumin biosynthesis. The first mechanism involves a chain extension reaction by cinnamic acid and 5 malonyl-CoA molecules that eventually arylized into a curcuminoid. The second mechanism involves two cinnamate units coupled together by malonyl-CoA. Both use cinnamic acid as their starting point, which is derived from the amino acid phenylalanine.[11]
Plant biosyntheses starting with cinnamic acid is rare compared to the more common p-coumaric acid.[11] Only a few identified compounds, such as anigorufone and pinosylvin, build from cinnamic acid.[12][13]
Curcumin biosynthesis diagram
malonyl-CoA (5)
Biosynthetic pathway of curcumin in Curcuma longa.[11]

Research[edit]

In vitro, curcumin exhibits numerous interference properties which may lead to misinterpretation of results.[5][6][14]
Although curcumin has been assessed in numerous laboratory and clinical studies, it has no medical uses established by well-designed clinical research.[15] According to a 2017 review of over 120 studies, curcumin has not been successful in any clinical trial, leading the authors to conclude that "curcumin is an unstable, reactive, non-bioavailable compound and, therefore, a highly improbable lead".[5]
Cancer studies using curcumin conducted by Bharat Aggarwal, formerly a researcher at the MD Anderson Cancer Center, were deemed fraudulent and subsequently retracted by the publisher.[16]

Pharmacology[edit]

Curcumin, which shows positive results in most drug discovery assays, is regarded as a false lead that medicinal chemists include among "pan-assay interference compounds" attracting undue experimental attention while failing to advance as viable therapeutic or drug leads.[5][6][17] In vitro, curcumin inhibits certain epigeneticenzymes (the histone deacetylasesHDAC1HDAC3HDAC8), transcriptional co-activator proteins (the p300 histone acetyltransferase)[18][19][20] and the arachidonate 5-lipoxygenase enzyme.[21]
In Phase I clinical trials, curcumin had poor bioavailability, was rapidly metabolized, retained low levels in plasma and tissues, and was extensively and rapidly excreted, factors that make its in vivo bioactivity unlikely and difficult to accurately assess.[5][22] Curcumin appears to reduce circulating C-reactive protein in human subjects, although no dose-response relationship was established.[23] Factors that limit the bioactivity of curcumin or its analogs include chemical instability, water insolubility, absence of potent and selective target activity, low bioavailability, limited tissue distribution, extensive metabolism, and potential for toxicity.[5]

Toxicity[edit]

Two preliminary clinical studies in cancer patients consuming high doses of curcumin (up to 8 grams per day for 3–4 months) showed no toxicity, though some subjects reported mild nausea or diarrhea.[24]

Alternative medicine[edit]

Despite concerns about safety or efficacy and the absence of reliable clinical research,[5][6] some alternative medicine practitioners give turmeric intravenously, supposedly as a treatment for numerous diseases, in one case causing a death in 2017.[25]

Adenosine kháng A431

Adenosine modulates cell growth in human epidermoid carcinoma ...

Adenosine kháng A431

From Wikipedia, the free encyclopedia
Adenosine
Adenosin.svg
Adenosine-3D-balls.png
Clinical data
Trade namesAdenocard; Adenocor; Adenic; Adenoco; Adeno-Jec; Adenoscan; Adenosin; Adrekar; Krenosin
AHFS/Drugs.comMonograph
Pregnancy
category
  • B
(adenosine may appear to be safe to the fetus in pregnant women)
Routes of
administration
Intravenous
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
BioavailabilityRapidly cleared from circulation via cellular uptake
Protein bindingNo
MetabolismRapidly converted to inosine and adenosine monophosphate
Biological half-lifecleared plasma <30 seconds – half-life <10 seconds
Excretioncan leave cell intact or can be degraded to hypoxanthine, xanthine, and ultimately uric acid
Identifiers
SynonymsSR-96225 (developmental code name)
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
ECHA InfoCard100.000.354
Chemical and physical data
FormulaC10H13N5O4
Molar mass267.241 g/mol
3D model (Jmol)
 Yes (what is this?)  (verify)
Adenosine is a purine nucleoside composed of a molecule of adenine attached to a ribose sugar molecule (ribofuranosemoiety via a β-N9-glycosidic bond.[1][2][3] Adenosine is widely found in nature and plays an important role in biochemicalprocesses, such as energy transfer—as adenosine triphosphate (ATP) and adenosine diphosphate (ADP)—as well as in signal transduction as cyclic adenosine monophosphate (cAMP). It is also a neuromodulator, believed to play a role in promoting sleep and suppressing arousal. Adenosine also plays a role in regulation of blood flow to various organs through vasodilation.[4][5][6]
In addition to adenosine's endogenous forms, it is also used as a medication, specifically, as an antiarrhythmic agent,[1][2][3] to treat a number of forms of supraventricular tachycardia that do not improve with vagal maneuvers.[7]Common side effects include chest pain, feeling faint, shortness of breath along with tingling of the senses .[7] Serious side effects include a worsening dysrhythmia and low blood pressure.[7] It appears to be safe in pregnancy.[7]

Medical uses[edit]

Diagnosis of supraventricular tachycardia[edit]

When it is administered intravenously, adenosine causes transient heart block in the atrioventricular (AV) node. This is mediated via the A1 receptor, inhibiting adenylyl cyclase, reducing cAMP and so causing cell hyperpolarization by increasing K+ efflux via inward rectifier K+ channels, subsequently inhibiting Ca2+ current.[8] It also causes endothelial-dependent relaxation of smooth muscle as is found inside the artery walls. This causes dilation of the "normal" segments of arteries, i.e. where the endothelium is not separated from the tunica media by atherosclerotic plaque. This feature allows physicians to use adenosine to test for blockages in the coronary arteries, by exaggerating the difference between the normal and abnormal segments.
The administration of adenosine also reduces blood flow to coronary arteries past the occlusion. Other coronary arteries dilate when adenosine is administered while the segment past the occlusion is already maximally dilated. This leads to less blood reaching the ischemic tissue, which in turn produces the characteristic chest pain.
In individuals suspected of suffering from a supraventricular tachycardia (SVT), adenosine is used to help identify the rhythm.

Antiarrhythmic agent[edit]

Certain SVTs can be successfully terminated with adenosine.[9] This includes any re-entrant arrhythmias that require the AV node for the re-entry, e.g., AV reentrant tachycardia (AVRT), AV nodal reentrant tachycardia (AVNRT). In addition, atrial tachycardia can sometimes be terminated with adenosine.

An electrocardiogram showing the conversion of SVT with adenosine
Fast rhythms of the heart that are confined to the atria (e.g., atrial fibrillationatrial flutter) or ventricles (e.g., monomorphic ventricular tachycardia) and do not involve the AV node as part of the re-entrant circuit are not typically converted by adenosine. However, the ventricular response rate is temporarily slowed with adenosine in such cases.
Because of the effects of adenosine on AV node-dependent SVTs, adenosine is considered a class V antiarrhythmic agent. When adenosine is used to cardiovert an abnormal rhythm, it is normal for the heart to enter ventricular asystolefor a few seconds. This can be disconcerting to a normally conscious patient, and is associated with angina-like sensations in the chest.[10]

Nuclear stress test[edit]

Adenosine is used as an adjunct to thallous (thallium) chloride TI 201 or Tc99m myocardial perfusion scintigraphy (nuclear stress test) in patients unable to undergo adequate stress testing with exercise.[11]

Dosage[edit]

When given for the evaluation or treatment of a supraventricular tachycardia (SVT), the initial dose is 6 mg to 12 mg, depending on standing orders or provider preference,[12] given as a rapid parenteral infusion. Due to adenosine's extremely short half-life, the IV line is started as proximal (near) to the heart as possible, such as the antecubital fossa. The IV push is often followed with an immediate flush of 10-20 ccs of saline. If this has no effect (i.e., no evidence of transient AV block), a dose of 12 mg can be given 1–2 minutes after the first dose. Some clinicians may prefer to administer a higher dose (typically 18 mg), rather than repeat a dose that apparently had no effect.[dubious ] When given to dilate the arteries, such as in a "stress test", the dosage is typically 0.14 mg/kg/min, administered for 4 or 6 minutes, depending on the protocol.
The recommended dose may be increased in patients on theophylline, since methylxanthines prevent binding of adenosine at receptor sites. The dose is often decreased in patients on dipyridamole (Persantine) and diazepam (Valium) because adenosine potentiates the effects of these drugs. The recommended dose is also reduced by half in patients presenting congestive heart failuremyocardial infarctionshockhypoxia, and/or hepatic or renal insufficiency, and in elderly patients.

Drug interactions[edit]

Dopamine may precipitate toxicity in a person. Carbamazepine may increase heart block. Dipyridamole potentiates the action of adenosine, requiring the use of lower doses.

Caffeine's principal mode of action is as an antagonist of adenosine receptors in the brain.
Methylxanthines (e.g., caffeine, found in coffee, or theophylline in tea, or theobromine, as found in chocolate) competitively antagonize adenosine's effects; an increased dose of adenosine may be required. By nature of caffeine's purine structure,[13] it binds to some of the same receptors as adenosine.[13] With the proviso that theophylline and theobromine cross the blood-brain barrier very poorly (thus, a low CNS effects on the heart), the pharmacological effects of adenosine may therefore be blunted in individuals taking large quantities of methylxanthines.[14][citation needed]

Contraindications[edit]

Common contraindications for adenosine are:
  • Second- or third-degree heart block (without a pacemaker)
  • Sick sinus syndrome (without a pacemaker)
  • Long QT syndrome
  • Severe hypotension
  • Decompensated heart failure
  • Asthma, traditionally considered an absolute CI. This is being contended and it is now considered a relative CI (however, selective adenosine antagonists are being investigated for use in treatment of asthma)[15]
  • Poison/drug-induced tachycardia
When administered via a central lumen catheter, adenosine has been shown to initiate atrial fibrillation because of its effect on atrial tissue. In individuals with accessory pathways, the onset of atrial fibrillation can lead to a life-threatening ventricular fibrillation. However, adenosine may be administered if equipment for cardioversion is immediately available as a backup.

Side effects[edit]

Many individuals experience facial flushing, a temporary rash on the chest, lightheadedness, diaphoresis, or nausea after administration of adenosine due to its vasodilatory effects. Metallic taste is a hallmark side-effect of adenosine administration. These symptoms are transitory, usually lasting less than one minute. It is classically associated with a sense of "impending doom", more prosaically described as apprehension. This lasts a few seconds after administration of a bolus dose, during transient asystole induced by intravenous administration. In some cases, adenosine can make patients' limbs feel numb for about 2–5 minutes after administration intravenously depending on the dosage (usually above 12 mg).

Pharmacological effects[edit]

Adenosine is an endogenous purine nucleoside that modulates many physiological processes. Cellular signaling by adenosine occurs through four known adenosine receptor subtypes (A1A2AA2B, and A3).[16]
Extracellular adenosine concentrations from normal cells are approximately 300 nM; however, in response to cellular damage (e.g. in inflammatory or ischemic tissue), these concentrations are quickly elevated (600–1,200 nM). Thus, in regard to stress or injury, the function of adenosine is primarily that of cytoprotection preventing tissue damage during instances of hypoxiaischemia, and seizure activity. Activation of A2A receptors produces a constellation of responses that in general can be classified as anti-inflammatory.[17]
In the US, Adenosine is marketed as Adenocard. In India Adenosine is sold as Adenoscan (Cipla)

Adenosine receptors[edit]

All adenosine receptor subtypes (A1, A2A, A2B, and A3) are G-protein-coupled receptors. The four receptor subtypes are further classified based on their ability to either stimulate or inhibit adenylate cyclase activity. The A1 receptors couple to Gi/o and decreases cAMP levels, while the A2 adenosine receptors couple to Gs, which stimulates adenylate cyclase activity. In addition, A1 receptors couple to Go, which has been reported to mediate adenosine inhibition of Ca2+ conductance, whereas A2B and A3 receptors also couple to Gq and stimulate phospholipase activity. Researchers at Cornell University have recently shown adenosine receptors to be key in opening the blood-brain barrier (BBB). Mice dosed with adenosine have shown increased transport across the BBB of amyloid plaque antibodies and prodrugs associated with Parkinson's disease, Alzheimer's, multiple sclerosis, and cancers of the central nervous system.[18]

Ghrelin/growth hormone secretagogue receptor[edit]

Adenosine is an endogenous agonist of the ghrelin/growth hormone secretagogue receptor.[19] However, while it is able to increase appetite, unlike other agonists of this receptor, adenosine is unable to induce the secretion of growth hormone and increase its plasma levels.[19]

Metabolism[edit]

Adenosine used as a second messenger can be the result of de novo purine biosynthesis via adenosine monophosphate (AMP), though it is possible other pathways exist.[20]
When adenosine enters the circulation, it is broken down by adenosine deaminase, which is present in red cells and the vessel wall.
Dipyridamole, an inhibitor of adenosine nucleoside transporter, allows adenosine to accumulate in the blood stream. This causes an increase in coronary vasodilatation.
Adenosine deaminase deficiency is a known cause of immunodeficiency.

Research[edit]

Viruses[edit]

The adenosine analog NITD008 has been reported to directly inhibit the recombinant RNA-dependent RNA polymerase of the dengue virus by terminating its RNA chain synthesis. This suppresses peak viremia and rise in cytokines and prevented lethality in infected animals, raising the possibility of a new treatment for this flavivirus.[21] The 7-deaza-adenosine analog has been shown to inhibit the replication of the hepatitis C virus.[22] BCX4430 is protective against Ebola and Marburgviruses.[23] Such adenosine analogs are potentially clinically useful since they can be taken orally.

Anti-inflammatory properties[edit]

Adenosine is believed to be an anti-inflammatory agent at the A2A receptor.[24][25] Topical treatment of adenosine to foot wounds in diabetes mellitus has been shown in lab animals to drastically increase tissue repair and reconstruction. Topical administration of adenosine for use in wound-healing deficiencies and diabetes mellitus in humans is currently under clinical investigation.
Methotrexate's anti-inflammatory effect may be due to its stimulation of adenosine release.[26]

Central nervous system[edit]

In general, adenosine has an inhibitory effect in the central nervous system (CNS). Caffeine's stimulatory effects are credited primarily (although not entirely) to its capacity to block adenosine receptors, thereby reducing the inhibitory tonus of adenosine in the CNS. This reduction in adenosine activity leads to increased activity of the neurotransmitters dopamine and glutamate.[citation needed] Experimental evidence suggests that adenosine and adenosine agonists can activate Trk receptorphosphorylation through a mechanism that requires the adenosine A2A receptor.[27]

Hair[edit]

Adenosine has been shown to promote thickening of hair on people with thinning hair.[28][29] A 2013 study compared topical adenosine to minoxidil in male androgenetic alopecia, finding it was not superior to minoxidil and further trials were needed.[30]